New England Journal of Medicine· 2019Q1

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Oliver Distler, Kristin B. Highland, Martina Gahlemann, Arata Azuma et al.

1,627citations
Q1SCImago
2019year

Short summary

Nintedanib slowed the annual decline in lung function by 41 ml/year in patients with systemic sclerosis-associated interstitial lung disease compared to placebo (P=0.04).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine